Summary
The goal of Lucero is to create autonomous micromanipulation solutions for biological applications integrating optical manipulation, microfluidics, and machine intelligence. Single-cell analysis is critical in many biomedical applications, such as clinical trials, in-vitro fertilization, forensic analysis, and single-cell omics. In fact, it is an ideal moment to enter the single-cell analysis market, because this market is valued at $1.4 billion globally and expected to keep on growing with a compound annual rate higher than 17%. While some techniques are already commercially available, single-cell approaches still have several limitations. Mechanical tools (e.g., motorised micropipettes and microneedles, centrifugation) are invasive and prone to damage the cells. Labeled-sorting methods (e.g., flow-cytometry) can affect cell viability for subsequent protocols. Non-invasive sorting procedures based on microfluidics require high amounts of cells and numerous repetitions to obtain a significant fraction of target cells. Furthermore, in all cases these methods require expert handling and are labor intensive. With Lucero, we propose a solution that overcomes these problems based on a smart optofluidic platform: contactless thanks to the use of optical tweezers, capable of controlling the local cellular environment thanks to the use of microfluidics, and capable of autonomous and accurate operation thanks to machine intelligence. Lucero will be compatible with standard microscopes already available in biomedical laboratories, permit to completely automatize single-cell protocols, and therefore drastically lower the cost of biomedical research. Lucero already counts with an outstanding core team of scientists and experienced business people, and it will provide ~20 jobs to university-educated individuals in the EU within the next 5 years. Lucero has already received initial funding and support from two different organizations that support and believe in Lucero's venture.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/957468 |
| Start date: | 01-09-2020 |
| End date: | 28-02-2022 |
| Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
The goal of Lucero is to create autonomous micromanipulation solutions for biological applications integrating optical manipulation, microfluidics, and machine intelligence. Single-cell analysis is critical in many biomedical applications, such as clinical trials, in-vitro fertilization, forensic analysis, and single-cell omics. In fact, it is an ideal moment to enter the single-cell analysis market, because this market is valued at $1.4 billion globally and expected to keep on growing with a compound annual rate higher than 17%. While some techniques are already commercially available, single-cell approaches still have several limitations. Mechanical tools (e.g., motorised micropipettes and microneedles, centrifugation) are invasive and prone to damage the cells. Labeled-sorting methods (e.g., flow-cytometry) can affect cell viability for subsequent protocols. Non-invasive sorting procedures based on microfluidics require high amounts of cells and numerous repetitions to obtain a significant fraction of target cells. Furthermore, in all cases these methods require expert handling and are labor intensive. With Lucero, we propose a solution that overcomes these problems based on a smart optofluidic platform: contactless thanks to the use of optical tweezers, capable of controlling the local cellular environment thanks to the use of microfluidics, and capable of autonomous and accurate operation thanks to machine intelligence. Lucero will be compatible with standard microscopes already available in biomedical laboratories, permit to completely automatize single-cell protocols, and therefore drastically lower the cost of biomedical research. Lucero already counts with an outstanding core team of scientists and experienced business people, and it will provide ~20 jobs to university-educated individuals in the EU within the next 5 years. Lucero has already received initial funding and support from two different organizations that support and believe in Lucero's venture.Status
CLOSEDCall topic
ERC-2020-POCUpdate Date
27-04-2024
Geographical location(s)
